Study: NCT00954512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Robatumumab
Description: In Part 1, robatumumab was to be administered at 10 mg/kg, 15 mg/kg (for Regimens B and C), or 20 mg/kg together with the assigned standard treatment. For Part 2, robatumumab was to be administered at the dose selected during Part 1, based upon the maximum tolerated dose (MTD) or maximum administered dose (MAD), pharmacokinetic (PK) and pharmacodynamic (PD) data.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Robatumumab
Description: In Part 1, robatumumab was to be administered at 10 mg/kg, 15 mg/kg (for Regimens B and C), or 20 mg/kg together with the assigned standard treatment. For Part 2, robatumumab was to be administered at the dose selected during Part 1, based upon the maximum tolerated dose (MTD) or maximum administered dose (MAD), pharmacokinetic (PK) and pharmacodynamic (PD) data.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Robatumumab
Description: In Part 1, robatumumab was to be administered at 10 mg/kg, 15 mg/kg (for Regimens B and C), or 20 mg/kg together with the assigned standard treatment. For Part 2, robatumumab was to be administered at the dose selected during Part 1, based upon the maximum tolerated dose (MTD) or maximum administered dose (MAD), pharmacokinetic (PK) and pharmacodynamic (PD) data.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Robatumumab
Description: In Part 1, robatumumab was to be administered at 10 mg/kg, 15 mg/kg (for Regimens B and C), or 20 mg/kg together with the assigned standard treatment. For Part 2, robatumumab was to be administered at the dose selected during Part 1, based upon the maximum tolerated dose (MTD) or maximum administered dose (MAD), pharmacokinetic (PK) and pharmacodynamic (PD) data.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Robatumumab
Description: In Part 1, robatumumab was to be administered at 10 mg/kg, 15 mg/kg (for Regimens B and C), or 20 mg/kg together with the assigned standard treatment. For Part 2, robatumumab was to be administered at the dose selected during Part 1, based upon the maximum tolerated dose (MTD) or maximum administered dose (MAD), pharmacokinetic (PK) and pharmacodynamic (PD) data.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Robatumumab
Description: In Part 1, robatumumab was to be administered at 10 mg/kg, 15 mg/kg (for Regimens B and C), or 20 mg/kg together with the assigned standard treatment. For Part 2, robatumumab was to be administered at the dose selected during Part 1, based upon the maximum tolerated dose (MTD) or maximum administered dose (MAD), pharmacokinetic (PK) and pharmacodynamic (PD) data.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel